2,3,4-trimethoxy-benzenesulfonic acid amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4-trimethoxy-benzenesulfonic acid amide
• 英文别名: 2,3,4-Trimethoxy-benzolsulfonsaeure-amid；2,3,4-Trimethoxybenzene-1-sulfonamide；2,3,4-trimethoxybenzenesulfonamide
• 化学式: C₉H₁₃NO₅S
• mdl: MFCD18897552
• 分子量: 247.272
• InChiKey: GOPREVNNVUSFEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  96.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1,2,3-三甲氧基苯 在 chlorosulphuric acid 、 氯仿 作用下， 生成 2,3,4-trimethoxy-benzenesulfonic acid amide
  参考文献：
  名称：

  Identification of Organic Compounds. III. Chlorosulfonic Acid as a Reagent for the Characterization of Aromatic Ethers^1,2

  摘要：

  DOI：

  10.1021/ja01860a049

文献信息

• [EN] USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS<br/>[FR] UTILISATIONS D'INHIBITEURS DE KINASE INDUCTIBLE PAR UN SEL (SIK) POUR TRAITER L'OSTÉOPOROSE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2018053373A1

  公开（公告）日：2018-03-22

  The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

  本公开提供了使用盐诱导激酶（SIK）抑制剂治疗和/或预防骨质疏松症的方法。还提供了使用SIK抑制剂增加成骨细胞功能、增加成骨细胞数量、增加成骨细胞活性、抑制骨骼吸收、减少破骨细胞数量、抑制破骨细胞活性、增加骨骼质量、下调SOST基因表达和/或抑制硬化蛋白活性的方法。SIK抑制剂可以与Src抑制剂或CSF I R抑制剂结合使用。典型的SIK抑制剂包括公式：（I）、（II）、（III）、（IV）、（V）或（VI）的化合物。
• [EN] BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'URÉE KINASE BICYCLIQUES ET LEURS UTILISATIONS
  申请人：BROAD INST INC

  公开号：WO2018009544A1

  公开（公告）日：2018-01-11

  The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

  本公开提供了公式(I)、(II)和(III)的化合物。所提供的化合物能够结合蛋白激酶（例如，SIK）并可能在调节（例如，抑制）主体或细胞中蛋白激酶（例如，SIK，例如，SIK1、SIK2或SIK3）的活性方面有用。所提供的化合物可能在治疗或预防需要治疗的主体中的疾病（例如，增殖性疾病、肌肉骨骼疾病、遗传性疾病、血液病、神经病、疼痛状况、精神障碍或代谢紊乱）方面有用。还提供了包括或涉及此处描述的化合物的药物组合物、试剂盒、方法和用途。
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2021237223A1

  公开（公告）日：2021-11-25

  The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and/or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.

  本公开提供了经修改的寡核苷酸及其组合物和方法。在某些实施方式中，提供的技术包括修改的糖或修改的核苷酸间连接。在某些实施方式中，本公开提供了用于制备修改的寡核苷酸的技术。在某些实施方式中，本公开提供了对手性控制的寡核苷酸组合物及其制备和用途的方法。
• Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor
  申请人：Chu Chester

  公开号：US20090030038A1

  公开（公告）日：2009-01-29

  The present invention relates to new compounds of formula I. (I) wherein R 1 to R 12 , X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式I的新化合物。(I)其中R1至R12、X、Q和n如公式I中所定义，或其盐、溶剂合物或溶剂化盐，其制备过程以及用于制备它们的新中间体，含有该化合物的制药配方以及该化合物在治疗中的使用。
• [EN] NAMPT INHBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE NAMPT ET LEURS UTILISATIONS
  申请人：REMEDY PLAN INC

  公开号：WO2022241257A1

  公开（公告）日：2022-11-17

  Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinucleotide (NAD), NAMPT signaling, a NAMPT pathway, and/or cellular metabolism. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Further provided are methods of manufacturing compounds of Formula (V). The compounds of the disclosure are of Formula (I), (II), (III), and (IV):

  本发明涉及调节（例如抑制）烟酰胺磷酸核糖转移酶（NAMPT）、烟酰胺单核苷酸（NMN）的产生、烟酰胺腺嘌呤二核苷酸（NAD）的产生、NAMPT信号传导、NAMPT途径和/或细胞代谢的化合物、方法、组合物、用途和试剂盒。在某些实施例中，这些化合物用于治疗疾病或疾病障碍。这些化合物可以通过靶向癌症干细胞来治疗癌症。在某些实施例中，这种癌症是结肠癌、胃癌、胃肠间质瘤、卵巢癌、肺癌、乳腺癌、胰腺癌、前列腺癌、睾丸癌、淋巴瘤、肝癌、子宫内膜癌、白血病或多发性骨髓瘤。此外，还提供了制造化合物公式（V）的方法。本公开的化合物为公式（I）、（II）、（III）和（IV）的化合物。